Analyze:
GSK:
$39.50
GlaxoSmithKline
GSK:
$39.50
Portfolio Monkey Estimate
Long-Term
Short-Term
You need to upgrade your Flash Player
-
Expected ReturnThis is Portfolio Monkey's estimate of how much GSK is expected to return on an annualized basis over a long-term investment horizon. Learn more about how Portfolio Monkey calculates this.Expected Return:
-1.2%
-
Volatility This is how much the security is likely to deviate from the expected return. The higher the volatility, the riskier it is. Learn moreExpected Volatility:
17.7%
- → GSK is more volatile than 39% of the securities in our database
- → GSK has a higher return potential than 22% of the securities in our database.
These securities are highly correlated to GSK and represent potential pair trade ideas.Pair Trade Ideas
Analyze a Security
Stock Headlines
- GSK GlaxoSmithKline picks Goldman partner for next CFO
- GSK FDA Asks For "Restraint" On Drug Safety Worries
- GSK Invest in India for Fast Growth
- GSK Glaxo Nabs Goldman's Half-Trillion-Pound Deal Maker
- GSK ViiV Healthcare Awards Southern Initiative Grants to Reduce HIV Disparities Among African Americans and Latinos
- GSK A.M. Vitals: Health-Overhaul Law Will Have 'Moderate' Spending Effect
- GSK InPlay: GlaxoSmithKline and Genmab announced the start of a Phase III study in non-Hodgkin's lymphoma
- GSK European stocks open lower; FTSE 100 drops 0.3%
- GSK Goldman Banker Named Glaxo C.F.O.
- GSK Dividends Aren't Enough: Drug Companies




